Trials / Completed
CompletedNCT04533997
Hypertonic Saline Therapy in Ambulatory Heart Failure Unit.
Efficacy and Safety of Ambulatory Hypertonic Saline Therapy in Outpatient Heart Failure Units.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 167 (actual)
- Sponsor
- Puerta de Hierro University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare intravenous furosemide (125 to 250 mg), isolated or in combination with hypertonic saline solution (2.6% to 3.4%) in the outpatient heart failure patient. The hypothesis is that the combination therapy will increase the diuresis volume at 3 hours and improve congestion parameters at 7 days.
Detailed description
This is a randomized, double-blind, multicenter study of all consecutive patients with decompensated heart failure and signs of volume overload who do not require hospital admission but require intravenous diuretic for relief of congestion. Patients meeting the inclusion criteria, with prior informed consent, will be randomized to treatment with furosemide with hypertonic saline versus isolated furosemide (control group). Complete clinical evaluation, echocardiography, and blood and urinary tests will be performed before the treatment. After 3 hours, diuresis volume, weight and urinary parameters will be evaluated. Efficacy and safety visits will be performed at 7 and 30 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hypertonic saline solution plus intravenous furosemide | Intravenous 60-minutes of hypertonic saline therapy plus furosemide: Furosemide: 125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide \> 160 mg Hypertonic saline solution: Na+ 125-134: 3.4%, Na+ 135-145: 2.6% |
| DRUG | Intravenous furosemide | Intravenous 60-minutes infusion of furosemide: 125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide \> 160 mg |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2023-05-10
- Completion
- 2023-09-30
- First posted
- 2020-09-01
- Last updated
- 2023-11-09
Locations
14 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04533997. Inclusion in this directory is not an endorsement.